Testing Objective Methods for Template Matching Ventricular Tachycardia and Pacemapping
Recruitment status was Recruiting
Patients sometimes suffer from life-threatening abnormal heart racing that originates from the lower chamber of the heart. These patients will often need an implantable defibrillator which has the ability to shock the heart back to a normal heart rhythm, but this does not prevent them from getting frequent recurrences of the bad heart rhythm needing shocks from the device. This can be painful and potentially harmful. Medicines to prevent recurrences of shocks are not very effective and have many side effects. An alternative to medicines for this is a procedure called a catheter ablation in which a wire is passed up through the blood vessels of the leg into the heart and used to find the short circuits which cause the dangerous heart rhythm. When the spot causing the trouble is found, the investigators can burn it ("ablate" it). This procedure is challenging and methods are needed to make it more effective and easier to do. One of the main ways for finding the short circuits involves using the electrocardiogram (the "ECG"). The regular ECG is simplistic and only makes use of recordings from 10 sites (6 precordial sites and 4 sites on both upper and lower limbs) on the body surface. The investigators are testing whether making recordings from 120 sites on the chest and back and using special computerized analysis of the recordings can help make catheter ablation for dangerous heart rhythms more effective.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Quantitative Measurements Comparing Body Surface Potentials During Pacemapping and Spontaneous Ventricular Tachycardia|
- Correlating the arithmetic markers (CORR and MAD) to the distance between the pacing site and origin of the ventricular tachycardia or the index pacing site. [ Time Frame: One year ] [ Designated as safety issue: No ]
|Study Start Date:||July 2010|
|Estimated Study Completion Date:||July 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
|focal VT .|
|Scar related VT, exit not identified|
|Scar related VT exit identified|
Hide Detailed Description
Several conventional and advanced mapping techniques are frequently utilized to accomplish a successful catheter ablation. Many of these mapping techniques (activation mapping, entrainment mapping) are hampered by either hemodynamic instability of some tachycardias or non-sustainability of others. Pacemapping is a commonly used tool for mapping non-sustained or hemodynamically unstable VT, which is based upon the principle that activation of the heart from a given site will yield a reproducible body surface electrocardiogram (ECG) morphology and that pacing from a site very close to the site at which VT activates the heart will result in a matching ECG morphology. This technique, however, is limited by imperfect accuracy and spatial resolution, subjectivity of interpretation leading to marked inter-observer variability in the perceived quality of a morphologic match, and by the need for an intuitive interpretation of the ECG to direct catheter manipulation. We hypothesize that one can improve the accuracy with which the origin of VT is localized by applying body surface potential mapping (BSPM), using data derived from 120 simultaneously acquired ECGs.
- To quantify the similarity between BSPM waveforms during induced VT and during pacemapping or between two different pacing sites using two waveform comparison metrics, the correlation coefficient (CORR) and the root mean square error (RMSE) and to test the validity of these metrics as markers of proximity of the pacing site to the site of earliest ventricular activation.
- To compare the accuracy with which the origin of ventricular tachycardia is localized via pacemapping by applying (BSPM), which uses data derived from 120 simultaneously acquired ECGs, to the accuracy of localization with different ECG subsets e.g. 12-lead ECG and X, Y and Z leads.
Patient and methods:
We anticipate that our patients will fall in one of the flowing 4 groups:
Group A:Patients with focal VT in structurally normal heart. Group B:Patients with scar related VT in which the exit site can be identified. Group C:Patients with scar related VT in which the exit site cannot be identified.Group D:Patients presenting with SVT.
For all groups, data for body-surface potential mapping (BSPM) will be recorded during induced VT (Group A& B), pacing from virtual VT exit sites which are several points selected around the scar margin to represent the VT exit site (group C) or index pacing site which is a pacing site selected as a reference in the RV of patients presented with SVT (group D) and from different pacemapping sites including successful and unsuccessful ablation sites if applicable. All data will be imported into customized software.
The improvement in the arithmetic value of the two comparison metrics will be tested as the site of pacing approaches the site of earliest ventricular activation (Groups A&B) or virtual VT exit sites in group C or the index pacing site (in group D). The best CORR and RMSE between the BSPM obtained during VT (in group A and B)/virtual VT exit sites (in group C) or index pacing site (group D) and different pacing sites (including successful and unsuccessful ablation sites) will be recorded. A simple linear regression will be used to compare the CORR and RMSE difference at each pacing site to distance between this pacing site and the successful ablation site as a surrogate of the best pace-match (in group A and B) or the corresponding virtual VT exit site (in group C) or index pacing site (group D). P value <0.05 will be considered significant. The mean sensitivity, specificity, and positive- and negative-predictive accuracies of the arithmetic metrics in determining the VT origin/exit site will be determined. We will repeat the previous protocol using different ECG subsets including 12 lead ECGs and X, Y and Z leads. The predictive accuracies for different subsets of electrodes will be measured and compared to those derived from using the whole BSPM obtained from the 120 ECG leads.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01170416
|Canada, Nova Scotia|
|Capital District Health Authority||Recruiting|
|Halifax, Nova Scotia, Canada, B3H 3A7|
|Contact: John Sapp, MD FRCPC 473 4272 email@example.com|
|Principal Investigator: John A Sapp, MD, FRCPC|
|Sub-Investigator: Ahmed El-Damaty, MD MSc|
|Principal Investigator:||John A Sapp, MD, FRCPC||Capital District Health Authority, Canada|